Asco-GU – Bicycle tries to put distance between itself and Seagen
However, results with BT8009, one of several datasets being presented this week at the Asco-GU conference, fail to convince many investors.
Xylocor sees enough to press on with angina gene therapy
A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?
